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INTRODUCTION
Autoantibodies to extractable nuclear antigens (ENAs) are im-
portant diagnostic markers for autoimmune diseases, such as 
systemic lupus erythematosus (SLE), Sjögren’s syndrome (SjS), 
and systemic sclerosis (SSc).1-3 These anti-ENAs exhibit strong 
clinical associations with several systemic autoimmune rheu-
matoid diseases (SARDs). Anti-Sm is considered to be a highly 
specific marker for SLE, anti-Scl-70 for SSc, and anti-RNP for 
SLE, SSc, and mixed connective tissue disease (MCTD).4,5 There-
fore, accurate detection of anti-ENAs plays a key role in the dif-
ferential diagnosis of SARDs. 
Several methods are available for the detection of anti-ENAs; 
however, no gold standard has been established due to the fol-
lowing reasons: 1) variations in substrates and fixatives, 2) dif-
ferences in methods and quantitation of results, and 3) difficul-
ty of establishing reference ranges.6 Over the years, gel-based 
immunoprecipitation techniques and ELISA have been wide-
ly used for the detection of anti-ENAs.7,8 ELISA assays are highly 
sensitive in measurements of the levels of antigens or antibod-
ies in various clinical samples, and it is one of the most com-
monly used diagnostic test in clinical and research laborato-
ries.9-11 Despite the advantages of ELISA assay, it is limited by 
laborious and long protocols. Several new methods with ac-
curate results and simplified laboratory procedures have been 
evaluated in various institutions to substitute conventional test-
ing methods for the detection of anti-ENAs.12,13
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Herein, we studied the overall performance of the automat-
ed fluorescent enzyme immunoassay (FEIA) technique for the 
detection of anti-ENAs and diagnosis of SARDs and compared 
the results with those of microplate ELISA.
MATERIALS AND METHODS
Serum samples
In this study, we collected non-duplicated and non-selected 
sera from 100 patients who underwent anti-ENA testing at one 
university hospital from December 2011 to January 2012. The 
appropriate sample size with which to evaluate the performance 
of the diagnostic tools was determined based on a previous re-
port.14 Of the 100 patients, 60 patients were diagnosed with well-
defined SARDs [25 SLE, 24 SjS, 5 rheumatoid arthritis (RA), 4 
MCTD, and 2 SSc]; 17 were diagnosed with non-SARD autoim-
mune disease, such as Raynaud disease, autoimmune carpal 
tunnel syndrome, or autoimmune disease with no criteria met 
for an exact diagnosis; 22 suffered from non-autoimmune dis-
eases, such as osteoarthritis, allergic rhinitis, and hypertensive 
heart disease; and 1 patient’s diagnosis was not available. The 
diagnosis of each patient with autoimmune disease was deter-
mined by expert rheumatologists. We received ethical approval 
of this study from the Institutional Review Board of Severance 
Hospital (IRB No. 1-2019-0013).
Autoantibody profiling methods 
We detected the most commonly measured ENA specificities, 
such as anti-SS-A/Ro, anti-SS-B/La, anti-RNP, anti-Sm, and an-
ti-Scl-70. Table 1 lists the nature of the antigens in the two tests 
that were evaluated. 
Microplate ELISA 
Microplate ELISA for detecting five different anti-ENAs were 
conducted using QUANTA LiteTM ELISA kits (INOVA Diagnostics, 
San Diego, CA, USA). Laboratory procedures were performed 
by expert technicians according to the manufacturer’s instruc-
tions, and manual sample preparation and manual distribution 
on the microplate initiated the wet process. After the procedure, 
the optical density (OD) of each reaction was measured by an 
ELISA reader, and the levels of autoantibodies were calculated 
using the values of OD from the patients’ sera and positive con-
trols. According to the manufacturer’s instructions, the results 
were reported in three categories: negative, weak positive, and 
positive. Semi-quantitative results of less than 20 units were 
classified as negative, 20–39 units as weak positive, and more 
than 40 units as positive. For statistical analyses, weak-positive 
results were considered positive results. 
Automated FEIA 
As previously described in the literature, the Phadia® 250 as-
say (Phadia, Uppsala, Sweden) utilizes polystyrene EliATM wells 
precoated with targeted antigens (SS-A/Ro protein, SS-B/La 
protein, RNP protein, SmD3 peptide, and Scl-70 protein, respec-
tively).15 The fluorescence emitted from the conjugate of the 
autoantibody was detected by a built-in fluorometer, and the es-
timated value was expressed in EliA U/mL. The results were clas-
sified in three categories: negative, equivocal, and positive. Ac-
cording to the cutoff values provided by the manufacturer, results 
less than 7 EliA U/mL were classified as negative, 7–10 EliA U/
mL as equivocal, and more than 10 EliA U/mL as positive. For 
statistical analyses, equivocal results were considered positive 
results. 
Statistical analyses
The statistical tests in this study were conducted using Anal-
yse-it® 3.90.4 (Analyse-it Software, Ltd., Leeds, UK) and R 3.5.3 
(R Foundation for Statistical Computing, Vienna, Austria). Agree-
ment between qualitative results from the two assays was as-
sessed using kappa coefficients. Recommended interpretations 
of kappa values were as follows: poor agreement, 0.01–0.20; fair 
agreement, 0.21–0.40; moderate agreement, 0.41–0.60; substan-
tial agreement, 0.61–0.80; and almost perfect agreement, 0.81–
0.99.16 Degrees of association between quantitative values from 
the two tests were assessed using Spearman’s correlation co-
efficients. A p value less than 0.05 was considered statistically 
significant. Sensitivity and specificity for each test were deter-
mined with two-by-two contingency tables. To define true posi-
tive, true negative, false positive, and false negative, a true event 
was defined as diagnosis of the patient with correlated disease. 
The sensitivities and specificities for the two methods were com-
pared by estimation of confidence intervals for differences in 
paired sensitivities and paired specificities.17,18 If the confidence 
limits for the differences in sensitivities or specificities did not 
include zero, there was evidence that the sensitivities or speci-
ficities were statistically different.18 As the clinical data of one 
patient was not available, analyses of diagnostic sensitivities 
Table 1. The Composition of Antigens in INOVA and Phadia® 250
Antigens INOVA Phadia® 250
SS-A/Ro Purified SS-A antigen (60 kDa and 52 kDa) Recombinant SS-A/Ro (60 kDa, 52 kDa) protein
SS-B/La Purified SS-B antigen Recombinant SS-B/La protein
RNP Purified RNP/Sm antigen complex Recombinant RNP (RNP70, A, C) protein
Sm Purified Sm antigen (BB, D1, D3, etc.)* Recombinant SmD3 peptide
Scl-70 Purified Scl-70 antigen Recombinant Scl-70 protein
*Targets all Sm autoantigen complexes, which consist of more than nine polypeptides
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and specificities were conducted with results from 99 patients.
RESULTS
Patients
The demographic data for the 99 patients are detailed in Table 2. 
Fifty-eight SARD patients were female (58/60, 96.7%), and 29 
non-SARD patients were female (29/39, 74.4%). The average age 
of the SARD patients was 37.0 years, with a standard deviation 
(SD) of 17.3, and in non-SARD patients, the average age was 
47.5 years, with a SD of 17.8. Sixty SARD patients comprised five 
different clinical diagnoses: SLE (n=25), SjS (n=24), RA (n=5), 
MCTD (n=4), and SSc (n=2). Non-SARD patients were subdi-
vided into a non-SARD autoimmune disease group (n=17) or 
non-autoimmune disease group (n=22).
Agreement between Phadia® 250 and microplate ELISA
Overall agreement values between Phadia® 250 and ELISA as-
say are listed in Table 3. Based on values of concordant and dis-
crepant results, the agreement rates between ELISA and Phad-
ia® 250 ranged from 89% for anti-RNP to 97% for anti-Scl-70. 
The estimated kappa coefficients for agreement between the 
results by the two assays had a minimum value of 0.44 for an-
ti-Sm and a maximum value of 0.82 for anti-SS-B/La. In detec-
tion of anti-Scl-70 and anti-Sm, the two methods showed mod-
erate agreement with kappa coefficients of 0.56 and 0.44, 
respectively. For anti-SS-A/Ro and anti-RNP, the two methods 
demonstrated substantial agreement. Correlation of signal to 
cut-off ratios was analyzed with Spearman’s rank correlation co-
efficients to document the degree of association between the 
two tests (Fig. 1). Spearman’s coefficients between the results by 
the two methods were 0.93 for anti-SS-A/Ro, 0.72 for anti-SS-B/
La, 0.43 for anti-RNP, 0.33 for anti-Sm, and 0.33 for anti-Scl-70.
Diagnostic performance of the two assays
The sensitivities and specificities of ELISA and Phadia® 250 in 
the detection of each anti-ENA antibody are shown in Table 4. 
As stated in the Materials and Methods section and Table 4, a 
true event in the evaluation of the diagnostic sensitivity and 
specificity of anti-SS-A/Ro was a diagnosis with SLE or SjS (to-
tal n=49). The rest of the diagnostic accuracy criteria for each 
autoantibody are detailed in the Table 4. According to the Clini-
cal and Laboratory Standards Institute guideline EP12-A, we 
used 95% confidence intervals to determine statistically dif-
ferent differences.18 In general, in the provided clinical context 
in Table 4, more false positive cases were observed with the ELI-
SA assay. Phadia® 250 showed higher sensitivity and specifici-
ty for the detection of anti-SS-A/Ro and anti Scl-70, although the 
difference was not statistically significant. Overall, there were 
no significant differences between the two assays, except for 
the specificity of anti-RNP and sensitivity of anti-Sm. 
DISCUSSION
In this study, we attempted to compare the overall performance 
of two laboratory platforms for the detection of anti-ENAs. Au-
tomated Phadia® 250 for the detection of anti-ENAs showed 
comparable performance with conventional microplate ELISA 
in that the two methods showed overall good analytical agree-
Table 2. Demographic Data of the 99 Patients 
SARD (n=60) Other (n=39) p value
Female, n (%) 58 (96.7) 29 (74.4) 0.003
Age (yr), mean±SD 37.0±17.3 47.5±17.8 0.005
Diagnosis, n (%) <0.001
Systemic lupus erythematosus 25 (41.7) -
Sjögren’s syndrome 24 (40.0) -
Rheumatoid arthritis 5 (8.3) -
Mixed connective tissue disease 4 (6.7) -
Systemic sclerosis 2 (3.3) -
Non-SARD autoimmune disease - 17 (43.6)
Non-autoimmune disease - 22 (56.4)
SARD, systemic autoimmune rheumatoid disease.
p value was calculated from Fisher’s exact test, comparison of values be-
tween SARD patients and other patients. p value lower than 0.05 was con-
sidered significant. 
Table 3. Comparison of the Results for Antibodies to Extractable Nuclear Antigens in INOVA and Phadia® 250 for a Total of 100 Serum Samples
Autoantibody
Concordant results Discrepant results*
Agreement rate (%)
Kappa coefficient 
(95% CI)
Spearman’s coefficient† 
(95% CI)Positive/ 
positive
Negative/ 
negative
Positive/ 
negative
Negative/ 
positive
Anti-SS-A/Ro 65 26 4 5 91 0.79 (0.66–0.92) 0.93 (0.90–0.96)
Anti-SS-B/La 23 70 6 1 93 0.82 (0.69–0.95) 0.72 (0.61–0.81)
Anti-RNP 16 73 11 0 89 0.68 (0.51–0.85) 0.43 (0.25–0.58)
Anti-Sm 4 87 9 0 91 0.44 (0.15–0.73) 0.33 (0.14–0.50)
Anti-Scl-70 2 95 3 0 97 0.56 (0.12–1.00) 0.33 (0.13–0.50)
CI, confidence interval.
*Shown as “no. of respective results by ELISA/Phadia® 250.” Weak positive samples (20–39 units) by ELISA and equivocal samples (7–10 EliA U/mL) by Phadia® 
250 were included as positive results, †Spearman’s rank correlation analysis was performed with signal to cut-off ratio values of the results by ELISA and Phad-
ia® 250, p values were <0.0001 for all autoantibodies.
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ment and that the diagnostic performance showed no statisti-
cally significant differences, except for anti-RNP and anti-Sm. 
Although there are no evaluation reports comparing the exact 
same methods of FEIA and ELISA in detecting anti-ENAs, our 
results are in line with a recent study comparing FEIA methods 
with enzyme immunoassays (EIA) and with a study comparing 
multiplexed flow immunoassay with conventional ELISA as-
say.12,13 In the previous study comparing EIA-based assay with 
FEIA, the two showed good agreement (kappa coefficient=0.70), 
and regarding clinical implications, the two showed compara-
ble results.12 In a study comparing FEIA with conventional in-
direct immunofluorescence assay, the percent agreement be-
tween the two assays was 79.2%, and FEIA showed higher 
sensitivity.19 In this context, where newly developed methods 
show comparable or even better performance than convention-
al immunoassays, practical consideration of the testing plat-
form based on the simplicity of the procedure, turnaround time, 
etc. could help to decide which platform to use in the laboratory. 
The clinical sensitivities of anti-Sm with Phadia® and ELISA 
were 0.120 and 0.400, which was a significant difference. Anti-
Sm has high diagnostic specificity in SLE patients, and clinical 
sensitivity has less correlation with establishing the diagnosis.5 
Even so, clinical correlation with diagnostic symptoms in pa-
tients prevents misdiagnosis with false negative results. The 
discrepant results in detecting anti-RNP (Table 3) could raise 
a question of misdiagnosis when using Phadia® 250. Out of 11 
discordant cases in the detection of anti-RNP, the diagnoses 
and semi-quantitative antibody titers, described as positive or 
weak positive, varied among the cases: SLE (weak positive, n=2; 
positive, n=2), SjS (weak positive, n=2; positive, n=2), MCTD 
(weak positive, n=1), and non-systemic autoimmune disease 
(weak positive, n=1; positive, n=1). As anti-RNP is a diagnostic 
marker for SLE and SSc and since a high level of anti-RNP is 
diagnostic of MCTD, this result could suggest the possibility of 
false positive cases according to clinical diagnoses, leading to 
misdiagnosis using the ELISA method.5 The problem of false-
positive anti-ENA tests has been continuously raised, and it is 
recommended that testing be performed with two different 
methods to avoid false-positive results.20,21 Clinical correlation 
with anti-ENA results can be another solution for avoiding false-
positive results. 
Our study is limited by the small number of patients with SARD 
and by the absence of normal healthy controls. Also, due to the 
high number of negative results for anti-Sm and anti-Scl-70 (Ta-
ble 3), we cannot accurately determine the degree of associa-
tion between the two methods in detecting these two antibod-
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Fig. 1. Spearman’s correlation plots of results from INOVA and Phadia® 250 for the five anti-ENAs. (A) anti-SS-A/Ro, (B) anti-SS-B/La, (C) anti-RNP, (D) anti-
Sm, and (E) anti-Scl-70. ENAs, extractable nuclear antigens.
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ies. Well-designed studies with a larger pool of patients would 
be helpful to determining the true diagnostic performances of 
the two methods. 
In this study, we evaluated and compared the analytical per-
formances of the automated FEIA platform Phadia® 250 and 
microplate ELISA (INOVA Diagnostics) for the detection of the 
five most commonly used anti-ENAs. Phadia® 250 showed com-
parable performance with conventional microplate ELISA. 
Since the selection of an assay for use in a clinical laboratory 
depends on several factors, such as protocol time, turnaround 
time, and simplicity of use by laboratory technicians, as well as 
the accuracy of test results, we believe that Phadia® 250 could 
be a useful and efficient method, as it shows comparable effi-
cacy and good agreement with previous methods, along with a 
shorter protocol time, a shorter turnaround time, and better ease 
of use than microplate ELISA.
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